Rosen Law Firm, a global investor rights law firm, is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) regarding allegations that the company may have issued materially misleading business information. The investigation centers on disclosures related to the company's bitopertin program and subsequent regulatory developments that impacted shareholder value.

On February 13, 2026, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Disc Medicine regarding its bitopertin program. The FDA stated it could not approve the company's new drug application (NDA) due to uncertainties requiring additional evidence. Following this announcement, Disc Medicine's stock price fell 22% on February 13, 2026.

The law firm is preparing a class action lawsuit seeking recovery of investor losses. Shareholders who purchased Disc Medicine securities may be entitled to compensation without payment of out-of-pocket fees or costs through a contingency fee arrangement. The firm encourages investors to select qualified counsel with a track record of success in leadership roles, noting that many firms issuing notices lack comparable experience or resources.

Investors wishing to join the prospective class action can visit the Rosen Law Firm's website or contact Phillip Kim, Esq. toll-free at 866-767-3653 or via email at case@rosenlegal.com for further information. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) regarding allegations that the company may have issued materially misleading business information. The investigation focuses on the impact of a regulatory decision that caused a significant decline in the company's stock price.

On February 13, 2026, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Disc Medicine regarding its bitopertin program. The FDA stated it could not approve the company's new drug application (NDA) due to uncertainties that would require additional evidence. Following this announcement, Disc Medicine's stock price fell 22% on February 13, 2026.

The law firm is preparing a class action lawsuit seeking recovery of investor losses. Shareholders who purchased Disc Medicine securities may be entitled to compensation through a contingency fee arrangement without any out-of-pocket fees or costs.

Investors who wish to join the prospective class action can contact the firm to discuss their rights. To join the prospective class action, interested parties can visit https://rosenlegal.com/submit-form/?case_id=56641 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com .

The investigation aims to determine if securities laws were violated in connection with the FDA's decision and the subsequent disclosure to the public. The Rosen Law Firm encourages investors to select qualified counsel with a track record of success in leadership roles.